These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 17420191)

  • 1. Effect of tobacco on INR.
    Garry J; Geraets DR
    Am J Health Syst Pharm; 2007 Apr; 64(8):804; author reply 805. PubMed ID: 17420191
    [No Abstract]   [Full Text] [Related]  

  • 2. Warfarin and bosentan interaction in a patient with pulmonary hypertension secondary to bilateral pulmonary emboli.
    Spangler ML; Saxena S
    Clin Ther; 2010 Jan; 32(1):53-6. PubMed ID: 20171411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Warfarin resistance.
    Sinxadi P; Blockman M
    Cardiovasc J Afr; 2008; 19(4):215-7. PubMed ID: 18776969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Warfarin pharmacogenetics: a controlled dose-response study in healthy subjects.
    Kadian-Dodov DL; van der Zee SA; Scott SA; Peter I; Martis S; Doheny DO; Rothlauf EB; Lubitz SA; Desnick RJ; Halperin JL
    Vasc Med; 2013 Oct; 18(5):290-7. PubMed ID: 24029542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon.
    Beinema M; Brouwers JR; Schalekamp T; Wilffert B
    Thromb Haemost; 2008 Dec; 100(6):1052-7. PubMed ID: 19132230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Probable warfarin and dapsone interaction.
    Truong T; Haley J
    Clin Appl Thromb Hemost; 2012; 18(1):107-9. PubMed ID: 21890570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Warfarin resistance with poor CYP2C9 activity and CYP2C9*1*2 genotype.
    Dericioglu N; Babaoglu MO; Saygi S; Bozkurt A; Yasar U
    Ann Pharmacother; 2004 May; 38(5):899. PubMed ID: 15039471
    [No Abstract]   [Full Text] [Related]  

  • 8. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.
    Carlquist JF; Horne BD; Muhlestein JB; Lappé DL; Whiting BM; Kolek MJ; Clarke JL; James BC; Anderson JL
    J Thromb Thrombolysis; 2006 Dec; 22(3):191-7. PubMed ID: 17111199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.
    Shaw K; Amstutz U; Hildebrand C; Rassekh SR; Hosking M; Neville K; Leeder JS; Hayden MR; Ross CJ; Carleton BC
    Pediatr Blood Cancer; 2014 Jun; 61(6):1055-62. PubMed ID: 24474498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral anticoagulation with warfarin is significantly influenced by steroids and CYP2C9 polymorphisms in children with cancer.
    Ruud E; Holmstrøm H; Bergan S; Wesenberg F
    Pediatr Blood Cancer; 2008 Mar; 50(3):710-3. PubMed ID: 17226852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of torsemide on pharmacodynamics and pharmacokinetics of warfarin in humans and rats.
    Kim HO; Lee KE; Park HY; Lee NR; Oh BR; Chang BC; Gwak HS
    J Pharm Pharmacol; 2013 Aug; 65(8):1195-203. PubMed ID: 23837587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms.
    Daly AK
    Arch Toxicol; 2013 Mar; 87(3):407-20. PubMed ID: 23376975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin.
    Teh LK; Langmia IM; Fazleen Haslinda MH; Ngow HA; Roziah MJ; Harun R; Zakaria ZA; Salleh MZ
    J Clin Pharm Ther; 2012 Apr; 37(2):232-6. PubMed ID: 21507031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Q: Should we use pharmacogenetic testing when prescribing warfarin?
    Rouse M; Cristiani C; Teng KA
    Cleve Clin J Med; 2013 Aug; 80(8):483-6. PubMed ID: 23908104
    [No Abstract]   [Full Text] [Related]  

  • 15. Probable interaction between warfarin and torsemide.
    Bird J; Carmona C
    Ann Pharmacother; 2008 Dec; 42(12):1893-8. PubMed ID: 19017829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delayed warfarin induced skin necrosis in a patient with poor warfarin metabolizing activity due to interrupted warfarin therapy.
    Gaikwad T; Ghosh K; Shetty S
    Eur J Clin Pharmacol; 2013 Feb; 69(2):293-4. PubMed ID: 22706625
    [No Abstract]   [Full Text] [Related]  

  • 17. Warfarin pharmacogenetics: ready for clinical utility?
    Baudhuin LM
    Clin Lab Sci; 2009; 22(3):151-5. PubMed ID: 19827409
    [No Abstract]   [Full Text] [Related]  

  • 18. An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients.
    Meckley LM; Wittkowsky AK; Rieder MJ; Rettie AE; Veenstra DL
    Thromb Haemost; 2008 Aug; 100(2):229-39. PubMed ID: 18690342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Warfarin sensitivity and genetic polymorphisms: should pharmacokinetic screening be part of anticoagulant dosing decisions?
    Baglin TP
    Clin Adv Hematol Oncol; 2003 Nov; 1(11):656-7. PubMed ID: 16258463
    [No Abstract]   [Full Text] [Related]  

  • 20. Reply to rebuttal: Gene variants of the cytochrome P450 CYP2C9 affect oral anticoagulation with warfarin.
    Margaglione M; Brancaccio V; Ciampa A; Di Minno G
    Thromb Haemost; 2001 Sep; 86(3):938. PubMed ID: 11583336
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.